Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
Status:
RECRUITING
Trial end date:
2054-09-01
Target enrollment:
Participant gender:
Summary
This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor red blood cell antibodies, achieving an event-free survival similar to transplanted patients without such antibodies.
Phase:
PHASE2
Details
Lead Sponsor:
Children's National Research Institute
Collaborators:
Alberta Children's Hospital Ann & Robert H Lurie Children's Hospital of Chicago Children's Hospital at Montefiore Doris Duke Charitable Foundation Janssen Pharmaceuticals Levine Children's Hospital Nationwide Children's Hospital The Hospital for Sick Children